Anthropic Moves From Scientific Workbench to In-House Drug Development, Pushing the Boundaries of Responsibility in AI Drug Discovery Further to the Front Line

When large technology companies bring AI into life sciences, the question is no longer just whether models can understand papers or organize experimental data, but how deeply they are prepared to bear the consequences of scientific judgment. After Anthropic launched Claude Science, according to foreign media reports, the company also indicated an interest in developing its own drug programs, meaning Claude may no longer be merely an assistant on researchers’ desks, but could become an active role in the drug discovery chain.

Anthropic released Claude Science on June 30, positioning it as an AI workbench for scientists, currently available in beta to Claude Pro, Max, Team, and Enterprise users. The tool integrates common scientific software, database queries, computing resources, and auditable records of research outputs, aiming to let researchers complete everything from data organization and analytical workflows to results traceability within the same environment.

In life science settings, Claude Science comes preconfigured with tools for genomics, single-cell analysis, proteomics, structural biology, cheminformatics, and more, and can access more than 60 scientific databases. Early tests cited by Anthropic include single-cell RNA sequencing analysis, CRISPR screen design, protein structure prediction, and small-molecule-related analysis; the product page also mentions that scientific objects such as proteins, sequence alignments, genome tracks, chemical structures, and PDFs can be incorporated into workflows.

A new layer of change is that The Verge reported Anthropic does not only want to provide scientific research software, but also hopes to develop its own drugs. The report said Eric Kauderer-Abrams, Anthropic’s head of life sciences, had hinted that the company may focus on treatments for neglected diseases. However, public information remains very limited: Anthropic has not yet explained specific diseases or candidate targets, nor has it stated whether laboratory validation, animal studies, clinical trials, or manufacturing would be carried out in partnership with external organizations.

This makes the significance of Claude Science more complex. If it is only a workbench, the core challenge is whether it can improve research efficiency, lower the barrier to data analysis, and leave a sufficiently clear chain of evidence. If Anthropic goes further and develops drugs in-house, the questions extend to the reproducibility, toxicity, pharmacokinetics, clinical feasibility, and regulatory responsibility of candidate molecules. AI can accelerate hypothesis generation, but it cannot replace wet-lab experiments, animal models, human trials, and regulatory review.

**Background Context**

In recent days, discussion around Claude Science has gradually shifted from “how AI enters scientific research workflows” to “who has the ability to use these tools, and who should be responsible for the results.” Anthropic emphasizes traceability and auditability precisely because biomedical research cannot look only at whether outputs are fluent; data sources, analysis parameters, model reasoning, and human judgment all affect whether credible evidence can ultimately be formed.

For rare or neglected diseases, an AI workbench may be able to reduce early exploration costs, allowing small research teams to organize literature, search databases, compare protein structures, or design screening strategies more quickly. But at present, Anthropic’s plan still appears to remain at a very early outline stage. The real dividing line is not whether AI can propose more candidate answers, but whether those answers can withstand biological validation and leave clear responsibility within the long, expensive, and highly regulated drug development process.